Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.42 -3.7%	$5.76	$4.35 ▼ $12.38	$322.73M	0.42	209,933 shs	152,620 shs
SNTI Senti Biosciences	$2.60 -9.1%	$3.37	$1.52 ▼ $16.94	$67.81M	2.23	805,885 shs	94,636 shs
TKNO Alpha Teknova	$5.48 -5.7%	$6.09	$1.16 ▼ $10.37	$292.86M	0.4	405,257 shs	193,994 shs
TRDA Entrada Therapeutics	$7.59 -3.3%	$8.21	$7.10 ▼ $21.79	$288.06M	-0.06	132,969 shs	117,868 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-3.75%	-1.23%	+31.02%	-12.65%	-11.33%
SNTI Senti Biosciences	-9.09%	-32.29%	-19.00%	-25.50%	-3.74%
TKNO Alpha Teknova	-5.68%	-7.59%	-15.95%	-1.79%	+214.94%
TRDA Entrada Therapeutics	-3.31%	-8.77%	-4.77%	-29.79%	-52.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.6757 of 5 stars	3.6	1.0	3.8	3.3	0.0
SNTI Senti Biosciences	2.3604 of 5 stars	3.5	3.0	1.9	0.0	1.3
TKNO Alpha Teknova	2.7938 of 5 stars	3.5	3.0	3.8	0.8	0.6
TRDA Entrada Therapeutics	2.8777 of 5 stars	3.6	2.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	242.68% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	226.92% Upside
TKNO Alpha Teknova	3.00	Buy	$8.50	55.11% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	238.16% Upside

Current Analyst Ratings Breakdown

Latest SNTI, AURA, TRDA, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/2/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/26/2025	AURA Aura Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/25/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$25.00
3/24/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
SNTI Senti Biosciences	$2.56M	26.49	N/A	N/A	$15.02 per share	0.17
TKNO Alpha Teknova	$38.25M	7.66	N/A	N/A	$2.21 per share	2.48
TRDA Entrada Therapeutics	$172.22M	1.67	N/A	N/A	$7.26 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$76.41M	-$1.90	N/A	N/A	N/A	N/A	-41.57%	-36.43%	8/8/2025 (Estimated)
SNTI Senti Biosciences	-$71.06M	-$10.84	N/A	N/A	N/A	N/A	-154.84%	-77.42%	8/12/2025 (Estimated)
TKNO Alpha Teknova	-$36.78M	-$0.48	N/A	N/A	N/A	-87.17%	-35.30%	-24.52%	N/A
TRDA Entrada Therapeutics	-$6.68M	$0.81	4.77	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)

Latest SNTI, AURA, TRDA, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A
3/20/2025	Q4 2024	SNTI Senti Biosciences	-$3.13	-$0.67	+$2.46	-$0.67	$2.80 million	$5.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.47	12.47
SNTI Senti Biosciences	N/A	1.92	1.92
TKNO Alpha Teknova	0.12	4.73	3.94
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
SNTI Senti Biosciences	25.73%
TKNO Alpha Teknova	13.81%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
SNTI Senti Biosciences	3.12%
TKNO Alpha Teknova	12.50%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.25 million	Not Optionable
SNTI Senti Biosciences	4	26.08 million	4.30 million	Not Optionable
TKNO Alpha Teknova	240	53.44 million	45.21 million	Not Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

SNTI, AURA, TRDA, and TKNO Headlines

Recent News About These Companies

Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell

June 14 at 2:16 AM | marketbeat.com

Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

June 12 at 3:08 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC

June 4, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.com

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025 | globenewswire.com

Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

May 24, 2025 | marketbeat.com

What is HC Wainwright's Estimate for TRDA Q2 Earnings?

May 23, 2025 | marketbeat.com

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 23, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 17, 2025 | marketbeat.com

MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 16, 2025 | marketbeat.com

Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst

May 16, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP

May 16, 2025 | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, AURA, TRDA, and TKNO Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.42 -0.25 (-3.75%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.40 -0.02 (-0.31%)

As of 06/13/2025 06:33 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Senti Biosciences NASDAQ:SNTI

$2.60 -0.26 (-9.09%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.67 +0.07 (+2.69%)

As of 06/13/2025 07:47 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Alpha Teknova NASDAQ:TKNO

$5.48 -0.33 (-5.68%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.48 +0.00 (+0.07%)

As of 06/13/2025 04:46 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Entrada Therapeutics NASDAQ:TRDA

$7.59 -0.26 (-3.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.59 0.00 (0.00%)

As of 06/13/2025 04:36 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time